Neuronetics (STIM) Cash & Equivalents (2016 - 2026)

Neuronetics (STIM) has 11 years of Cash & Equivalents data on file, last reported at $13.2 million in Q1 2026.

• Cash & Equivalents for Q1 2026 came in at $13.2 million, down 34.66% year-over-year; the trailing twelve-month figure through Mar 2026 was $13.2 million (down 34.66% YoY), and the FY2025 annual result was $6.0 million, up 500.0% from the prior year.
• Cash & Equivalents rose to $13.2 million in Q1 2026 per STIM's latest filing, from $6.0 million in the prior quarter.
• Over five years, Cash & Equivalents peaked at $80.8 million in Q1 2022 and troughed at $1.0 million in Q4 2024.
• A 5-year average of $39.9 million and a median of $42.6 million in 2024 frame the typical range for Cash & Equivalents.
• The sharpest annual moves came in 2024 and 2025: Cash & Equivalents slumped 98.32% in 2024, then surged 500.0% in 2025.
• A 5-year view of Cash & Equivalents shows it stood at $70.3 million in 2022, then fell by 15.16% to $59.7 million in 2023, then tumbled by 98.32% to $1.0 million in 2024, then surged by 500.0% to $6.0 million in 2025, then surged by 120.23% to $13.2 million in 2026.
• Business Quant data shows STIM's Cash & Equivalents at $13.2 million in Q1 2026, $6.0 million in Q4 2025, and $28.0 million in Q3 2025.